1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)

L Notario Rincon,C Hierro,A Esteve,S Fontanals,A González,E Loureiro,C Sun,M Margelí,T Moran,A Font,J.L Manzano,C Balaña,V Quiroga,N Quer,C Ibañez,J Martínez-Benavides,J Brunet,A Clopes,R Mesia

doi:10.1016/j.annonc.2021.08.837

1508MO Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)

L Notario Rincon, C Hierro + Show 17 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.837

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

Affiliation: Institut Català d'Oncologia, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol

#Off-label Drugs #Program For Cancer Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Molecularly targeted agents (MTA) and immunotherapies (IO) are approved for cancer pt. OLD can be used before the upcoming approval and in different scenarios or conditions from those reflected in regulatory summary approvals. ME programs allow pt to receive OLD. We aimed to improve ME pt selection by developing a prognostic score (ICO MEscore) that included clinic-analytical (CA) variables readily available in real practice.

Full Text